(Q37853578)

English

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

scientific article published on 17 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? (English)

1 reference

Europe PubMed Central

24 August 2017

multiple drug resistance

1 reference

based on heuristic

inferred from title

author name string

Anna Brózik

1

1 reference

Europe PubMed Central

24 August 2017

Csilla Hegedüs

2

1 reference

Europe PubMed Central

24 August 2017

Zsuzsa Erdei

3

1 reference

Europe PubMed Central

24 August 2017

Tamás Hegedus

4

1 reference

Europe PubMed Central

24 August 2017

Csilla Özvegy-Laczka

5

1 reference

Europe PubMed Central

24 August 2017

Gergely Szakács

6

1 reference

Europe PubMed Central

24 August 2017

Balázs Sarkadi

7

1 reference

Europe PubMed Central

24 August 2017

language of work or name

0 references

publication date

17 March 2011

1 reference

Europe PubMed Central

24 August 2017

Expert Opinion on Drug Metabolism & Toxicology

1 reference

Europe PubMed Central

24 August 2017

7

1 reference

Europe PubMed Central

24 August 2017

5

1 reference

Europe PubMed Central

24 August 2017

623-642

1 reference

Europe PubMed Central

24 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Targeting multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Structure, function, and evolution of bacterial ATP-binding cassette systems

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The role of ABC transporters in drug resistance, metabolism and toxicity

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Transport proteins of the ABC family and multidrug resistance of tumor cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Drug transport by breast cancer resistance protein.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Molecular basis of multidrug transport by ABC transporters

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The multidrug transporters--proteins of an ancient immune system

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

A dual-fluorescence high-throughput cell line system for probing multidrug resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Use of in vivo animal models to assess pharmacokinetic drug-drug interactions

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Applications and limitations of genetically modified mouse models in drug discovery and development

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

ABCC2/Abcc2 transport property in different species and its modulation by heterogeneous factors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Specific inhibitors of the breast cancer resistance protein (BCRP).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Metabolism and disposition of imatinib mesylate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Stem cell concepts renew cancer research

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Stemming cancer: functional genomics of cancer stem cells in solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Cancer stem cells: controversial or just misunderstood?

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Cancer stem cells and survival pathways

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Tumour stem cells and drug resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

A distinct "side population" of cells with high drug efflux capacity in human tumor cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Identification of compounds selectively killing multidrug-resistant cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Characterization of gene rearrangements leading to activation of MDR-1.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Gene rearrangement: a novel mechanism for MDR-1 gene activation

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The direct activation of human multidrug resistance gene (MDR1) by anticancer agents

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Nuclear receptor drug discovery

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Physiological, pharmacological and clinical features of the multidrug resistance protein 2.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cells.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Human pregnane X receptor and resistance to chemotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Cancer cell adaptation to chemotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Human ATP-binding cassette (ABC) transporter family

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

ABC transporters in cancer: more than just drug efflux pumps.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Pharmacokinetic considerations for new targeted therapies.

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.562892

21 January 2018

Identifiers

10.1517/17425255.2011.562892

1 reference

Europe PubMed Central

24 August 2017

1 reference

Europe PubMed Central

24 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37853578&oldid=2147278962"